Related Articles
Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)
Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease
Treatment of experimental non‑alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor‑mediated inflammatory responses in mice
Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes